Search Grant Opportunities

DoW Multiple Sclerosis Clinical Trial Award

ID: HT942526MSRPCTA • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Popular Questions:
Generate a draft:

Description

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.

Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:

Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.

Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.

For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.

Background
The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) is administered by the Defense Health Agency (DHA). It aims to support the rapid implementation of clinical trials that can significantly impact the treatment or management of multiple sclerosis. The MSRP was initiated by Congress in 2009 to fund high-potential research with exceptional scientific merit. This research focuses on preventing, curing, reversing, or slowing the progression of multiple sclerosis for the benefit of Service Members, Veterans, and their families.

Grant Details
The FY26 CTA supports two funding levels: Funding Level 1 (CTA-FL1) for small-scale, proof-of-principle clinical trials requiring preliminary data relevant to the proposed trial; and Funding Level 2 (CTA-FL2) for larger-scale phase 1 or phase 2 trials demonstrating safety or efficacy in relevant patient populations. Each application must address at least one focus area: promoting repair and neuroprotection in MS or treating MS symptoms. The maximum funding caps are $1.0M for CTA-FL1 and $2.0M for CTA-FL2. The total expected allotment for this program is approximately $4.0M, with awards anticipated to be made no later than September 30, 2027.

Eligibility Requirements
Eligible applicants include extramural and intramural U.S. Department of War organizations, both foreign and domestic, including for-profit and nonprofit entities. Principal Investigators must be independent investigators affiliated with an eligible organization at any career level but may only be named as PI on one application per funding level.

Period of Performance
The maximum period of performance is up to 3 years for CTA-FL1 applications and up to 4 years for CTA-FL2 applications.

Grant Value
The total value of the grant is approximately $4.0M, with individual grant awards capped at $1.0M for CTA-FL1 and $2.0M for CTA-FL2.
Show All

Overview

Agency
U.S. Army Medical Research Acquisition Activity (USAMRAA) [DoD - USA - MEDCOM - MRDC]
Category of Funding
Science and Technology and other Research and Development
Funding Instruments
Grant
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
Grants.gov
On 5/5/26 U.S. Army Medical Research Acquisition Activity posted grant opportunity HT942526MSRPCTA for DoW Multiple Sclerosis Clinical Trial Award with funding of $4.0 million. The grant will be issued under grant program 12.420 Military Medical Research and Development. It is expected that 3 total grants will be made.

Timing

Posted Date
May 5, 2026, 12:00 a.m. EDT
Closing Date
Aug. 13, 2026, 12:00 a.m. EDT Due in 86 Days
Last Updated
May 5, 2026, 9:50 a.m. EDT
Version
1
Archive Date
Sept. 12, 2026

Eligibility

Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Award Sizing

Ceiling
Not Listed
Floor
Not Listed
Estimated Program Funding
$4,000,000
Estimated Number of Grants
3

Contacts

Contact
JoAnn Martin Grantor
Contact Email
help@ebrap.org   Profile
Email Description
CDMRP Help Desk
Contact Phone
(301) 619-2594

Documents

Posted documents for HT942526MSRPCTA

Opportunity Assistant

AI Analysis
AI Generate

Potential Applicants and Partners

Awardees that have recently won grants similar to HT942526MSRPCTA

Incumbent or Similar Grants

Grants similar to HT942526MSRPCTA

Similar Active Opportunities

Open grant opportunities similar to HT942526MSRPCTA

Experts for DoW Multiple Sclerosis Clinical Trial Award

Recommended subject matter experts available for hire